European Commission Approves Teclistamab Monotherapy for Relapsed/Refractory Multiple Myeloma

The European Commission has approved an expanded indication for Johnson & Johnson's TECVAYLI (teclistamab) monotherapy for adult patients with relapsed/refractory multiple myeloma who have received at least one prior therapy. This approval provides an additional immunotherapy option in earlier lines of treatment, supported by significant improvements in both progression-free and overall survival.